Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Related BMY
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Thursday Morning Earnings Reports
Drug Giants Advance Cancer Treatments (Fox Business)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Most Popular

Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters